Recombinant Human Brain Natriuretic Peptide for Injection.

Effects and efficacy:
Recombinant human brain natriuretic peptide is suitable for the treatment of patients with acute heart failure who have dyspnea at rest or during slight activity, and whose NYHA classification is greater than class II.
Usage and dosage:
The dosage range of recombinant human brain natriuretic peptide for injection is loading dose: 1.5-2μg/kg, maintenance dose rate: 0.0075-0.01μg/kg/min, continuous intravenous drip for 24 hours. The specific usage and dosage for different populations and different diseases need to be determined by experienced clinicians.
Adverse reactions:
Common adverse reactions The most common adverse reaction to the administration of recombinant human brain natriuretic peptide is hypotension. Other adverse reactions are mostly manifested as abdominal pain, back pain, nausea, anxiety, fever, injection site reaction, paresthesia, confusion, drowsiness, tremor, cough, apnea, sweating, itching, eczema, lower limb cramps, amblyopia, increased creatinine, anemia, etc. Cardiovascular events also include ventricular premature beats, ventricular tachycardia, sinus bradycardia, and angina pectoris.
Contraindications:
Contraindicated if allergic to this product Use with caution during pregnancy Use with caution during breastfeeding Use with caution in children